Amalgamated Bank Cuts Stock Position in Encompass Health Co. (NYSE:EHC)

Amalgamated Bank lowered its position in Encompass Health Co. (NYSE:EHCGet Rating) by 1.3% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 71,754 shares of the company’s stock after selling 968 shares during the period. Amalgamated Bank owned approximately 0.07% of Encompass Health worth $5,102,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Meeder Asset Management Inc. purchased a new stake in Encompass Health during the 1st quarter worth approximately $33,000. Worth Asset Management LLC purchased a new stake in Encompass Health during the 1st quarter worth approximately $35,000. Covestor Ltd purchased a new stake in Encompass Health during the 4th quarter worth approximately $38,000. Allworth Financial LP grew its position in Encompass Health by 83.1% during the 1st quarter. Allworth Financial LP now owns 630 shares of the company’s stock worth $45,000 after purchasing an additional 286 shares during the last quarter. Finally, Rather & Kittrell Inc. purchased a new stake in Encompass Health during the 4th quarter worth approximately $49,000. Hedge funds and other institutional investors own 93.07% of the company’s stock.

Encompass Health Stock Performance

EHC opened at $51.32 on Tuesday. The company has a debt-to-equity ratio of 1.29, a current ratio of 1.24 and a quick ratio of 1.24. The firm has a fifty day moving average price of $50.73 and a 200 day moving average price of $59.44. Encompass Health Co. has a 1 year low of $44.33 and a 1 year high of $78.31. The stock has a market cap of $5.12 billion, a P/E ratio of 15.69, a P/E/G ratio of 2.41 and a beta of 1.02.

Encompass Health (NYSE:EHCGet Rating) last posted its earnings results on Monday, August 1st. The company reported $0.89 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.97 by ($0.08). Encompass Health had a net margin of 6.22% and a return on equity of 16.20%. The firm had revenue of $1.33 billion during the quarter, compared to analyst estimates of $1.34 billion. During the same quarter in the prior year, the firm earned $1.17 earnings per share. The business’s revenue for the quarter was up 3.3% on a year-over-year basis. Equities research analysts anticipate that Encompass Health Co. will post 2.88 earnings per share for the current year.

Encompass Health Cuts Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, October 17th. Shareholders of record on Monday, October 3rd will be given a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a yield of 1.17%. The ex-dividend date of this dividend is Friday, September 30th. Encompass Health’s dividend payout ratio is presently 34.25%.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Encompass Health from $80.00 to $62.00 in a research report on Wednesday, August 3rd. TheStreet cut shares of Encompass Health from a “b-” rating to a “c+” rating in a research note on Tuesday, June 28th. Barclays decreased their price objective on shares of Encompass Health from $80.00 to $63.00 and set an “overweight” rating for the company in a research note on Thursday, August 4th. Royal Bank of Canada decreased their price objective on shares of Encompass Health from $82.00 to $66.00 in a research note on Wednesday, August 24th. Finally, Stephens decreased their price objective on shares of Encompass Health from $78.00 to $74.00 and set an “overweight” rating for the company in a research note on Tuesday, June 21st. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Encompass Health has a consensus rating of “Buy” and a consensus target price of $70.10.

Insiders Place Their Bets

In other Encompass Health news, CEO Mark J. Tarr sold 20,449 shares of the company’s stock in a transaction on Wednesday, August 17th. The shares were sold at an average price of $53.25, for a total transaction of $1,088,909.25. Following the completion of the transaction, the chief executive officer now directly owns 440,895 shares in the company, valued at $23,477,658.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.70% of the stock is currently owned by company insiders.

Encompass Health Profile

(Get Rating)

Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates in two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.

Further Reading

Want to see what other hedge funds are holding EHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Encompass Health Co. (NYSE:EHCGet Rating).

Institutional Ownership by Quarter for Encompass Health (NYSE:EHC)

Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.